Compare LIND & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | XERS |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2011 | 2021 |
| Metric | LIND | XERS |
|---|---|---|
| Price | $22.36 | $5.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $22.25 | $10.83 |
| AVG Volume (30 Days) | 741.7K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 100.00 |
| EPS | ★ 0.09 | 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $10.98 | $34.37 |
| Revenue Next Year | $6.98 | $22.86 |
| P/E Ratio | ★ $255.11 | $607.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $10.46 | $4.30 |
| 52 Week High | $23.78 | $10.08 |
| Indicator | LIND | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 44.01 |
| Support Level | $16.26 | $5.81 |
| Resistance Level | N/A | $6.42 |
| Average True Range (ATR) | 0.92 | 0.24 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 73.42 | 20.16 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.